Coronary Artery Disease

Clinical Trial Finder

Many patients with coronary artery disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

HeartHab, Can a Patient-tailored Application Support Coronary Artery Disease Patients During Rehabilitation?

Condition:   Coronary Artery Disease
Intervention:   Behavioral: HeartHab application intervention
Sponsor:   Hasselt University
Not yet recruiting - verified January 2016

The Effect of Resistance Training on Proprotein Subtilisin Convertase Kexin 9 Level After Coronary Bypass Surgery

Condition:   Coronary Artery Disease
Interventions:   Behavioral: resistance training;   Behavioral: aerobic training
Sponsor:   National Cardiovascular Center Harapan Kita Hospital Indonesia
Not yet recruiting - verified February 2016

MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: MDCO-216;   Drug: Placebo
Sponsors:   The Medicines Company;   The Cleveland Clinic
Recruiting - verified February 2016

Remote Ischemic Preconditioning to Prevent Contrast Nephropathy

Condition:   Acute Kidney Injury
Intervention:   Procedure: Remote ischemic preconditioning
Sponsor:   Johns Hopkins University
Recruiting - verified February 2016

Danlou Tablets to Prevent Left Ventricular Remodeling

Conditions:   Left Ventricular Remodeling;   Acute Myocardial Infarction
Interventions:   Drug: Danlou Tablets;   Other: Placebo
Sponsor:   shuai Mao
Completed - verified February 2016

Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?

Condition:   Coronary Artery Disease
Interventions:   Procedure: Coronary PCI with OCT with Co Registration;   Procedure: Coronary PCI with OCT without Co Registration
Sponsors:   St. Francis Hospital, New York;   CardioVascular Research Foundation, Korea
Recruiting - verified February 2016

Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease

Condition:   Heart Failure
Intervention:   Biological: CSCC_ASC
Sponsors:   JKastrup;   European Union
Not yet recruiting - verified February 2016

Accelerated Rule Out of Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Procedure: Accelerated, combined biomarker rule-out strategy for MI
Sponsor:   Aarhus University Hospital Skejby
Recruiting - verified February 2016

Increasing Exercise and Decreasing Sedentary Behavior Among Patients in a Cardiac Rehabilitation Clinic

Conditions:   Acute Coronary Syndrome;   Heart Failure;   Other Cardiac Conditions Among Cardiac Rehabilitation Participants
Interventions:   Other: B-MOBILE-CARDIAC smartphone application;   Behavioral: Cardiac rehabilitation as usual
Sponsor:   The Miriam Hospital
Not yet recruiting - verified February 2016

A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction

Conditions:   Myocardial Infarction With/Without ST Segment Elevation;   Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells
Interventions:   Biological: Stem cells;   Other: Placebo
Sponsor:   Altaco XXI, LLP
Recruiting - verified February 2016

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Not yet recruiting - verified February 2016

Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology

Condition:   Heart Failure,Congestive
Intervention:  
Sponsor:   Jing Huang
Recruiting - verified February 2016

Preload Dependency Evaluation With Stroke Volume Variation During Alveolar Recruitment Manoeuvres

Conditions:   Coronary Artery Disease;   Coronary Artery Bypass;   Hypovolemia;   Anesthesia, General;   Pulmonary Atelectasis
Interventions:   Other: tee measurement;   Other: flotrac measurement;   Other: clearsight measurement
Sponsor:   University Hospital, Clermont-Ferrand
Not yet recruiting - verified February 2016

Distal Renal Denervation

Condition:   Hypertension, Resistant to Conventional Therapy
Interventions:   Procedure: Distal renal denervation;   Procedure: Conventional renal denervation
Sponsor:   Federal State Budgetary Scientific Institution, Research Institute of Cardiology
Active, not recruiting - verified January 2016

Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Condition:   Acute Coronary Syndrome
Intervention:   Other: This is a non-interventional study
Sponsor:   Drug Safety Research Unit, Southampton, UK
Recruiting - verified February 2016

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)

Condition:   Acute Myocardial Infarction
Interventions:   Drug: PROTHERACYTES;   Device: Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)
Sponsor:   CellProthera
Recruiting - verified February 2016

Electrical Stimulation Improves Exercise Tolerance in Patients With Advanced Heart Failure on Continuous Dobutamine Use

Conditions:   Heart Failure;   Ventricular Dysfunction, Left
Interventions:   Device: Neuromuscular Electrical Stimulator;   Other: Physical Therapy Session
Sponsor:   Federal University of São Paulo
Completed - verified January 2016

Sevoflurane and Percutaneous Coronary Intervention by Stent

Condition:   Myocardial Infarction
Intervention:   Drug: sevoflurane
Sponsor:   Instituto Dante Pazzanese de Cardiologia
Not yet recruiting - verified January 2016

Knowledge Translation for Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Behavioral: knowledge translation
Sponsors:   Montreal General Hospital;   Sanofi;   Canadian Institutes of Health Research (CIHR);   Fonds de la Recherche en Santé du Québec
Completed - verified January 2016

Comparative Effectiveness of Health System vs. Multilevel Interventions to Reduce Hypertension Disparities

Condition:   Uncontrolled Hypertension
Interventions:   Behavioral: Provider Audit-Feedback;   Behavioral: Provider Audit-Feedback, Stratified by race, ethnicity, payor status;   Behavioral: Blood Pressure Measurement Standardization;   Behavioral: System Level Leadership Intervention;   Behavioral: Collaborative Care Team Intervention;   Behavioral: Community Health Worker;   Behavioral: Specialist Care
Sponsors:   Johns Hopkins University;   National Heart, Lung, and Blood Institute (NHLBI);   Mid-Atlantic Association of Community Health Centers;   Patient-Centered Outcomes Research Institute
Not yet recruiting - verified February 2016

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

Conditions:   Coronary Disease;   Shock, Cardiogenic;   Renal Failure;   Stroke;   Brain Injury;   Aortic Valve Disease
Interventions:   Drug: Byetta (Lilly, Exenatide);   Drug: Conoxia (AGA, oxygen);   Drug: 20% Human Albumin
Sponsor:   Rigshospitalet, Denmark
Not yet recruiting - verified February 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events (OXI)

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Recruiting - verified February 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified January 2016

Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients

Condition:   Coronary Artery Disease
Interventions:   Drug: Vericiguat (BAY1021189);   Drug: Placebo;   Drug: Nitroglycerin
Sponsors:   Bayer;   Merck Sharp & Dohme Corp.
Recruiting - verified January 2016

EVOLVE Short DAPT Study

Condition:   Coronary Artery Disease
Interventions:   Drug: 3 months of dual antiplatelet therapy (DAPT);   Device: SYNERGY Stent System
Sponsor:   Boston Scientific Corporation
Recruiting - verified February 2016

Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study

Condition:   Unstable Angina Pectoris
Interventions:   Drug: Pulverized ticagrelor sublingually;   Drug: Pulverized ticagrelor orally;   Drug: Integral ticagrelor
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified February 2016

EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors

Condition:   Alopecia
Interventions:   Other: CG428;   Other: Placebo
Sponsors:   Samsung Medical Center;   Legacy Healthcare Services
Recruiting - verified January 2016

Testing a Community Intervention to Increase Aspirin Use

Conditions:   Myocardial Infarction;   Stroke
Interventions:   Other: Mass Media plus clinic intervention.;   Other: Media
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified February 2016

Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)

Condition:   Atrial Fibrillation
Interventions:   Behavioral: moderate-intensity continuous exercise training;   Behavioral: high-intensity interval training
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified November 2015

Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)

Condition:   Anterior Wall Acute Myocardial Infarction
Intervention:   Device: SSO2 Therapy
Sponsor:   TherOx
Recruiting - verified February 2016

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Conditions:   Angina, Stable;   Angina, Unstable;   Anticoagulants
Interventions:   Device: COBRA PzF;   Device: DES
Sponsor:   CeloNova BioSciences, Inc.
Recruiting - verified February 2016

The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment

Conditions:   Homocysteine;   Coronary Disease;   Angioplasty,Balloon,Coronary;   Contrast Media;   Nephropathy;   Hypertension
Interventions:   Drug: Enalapril Maleate Tablets(as the program-based antihypertension);   Drug: Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension);   Drug: Placebo
Sponsor:   Fuling Central Hospital of Chongqing City
Recruiting - verified February 2016

Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings

Conditions:   Myocardial Ischemia;   Hemorrhage;   Quality of Life;   Platelet Aggregation Inhibitors
Interventions:   Behavioral: good clinical practice;   Behavioral: bundle group
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Coronary Artery Aneurysm Registry

Condition:   Coronary Artery Aneurysm
Intervention:  
Sponsor:   St Carlos Hospital, Madrid, Spain
Recruiting - verified September 2015

Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)

Conditions:   Secondary Prevention;   Stroke;   Ischemic Heart Disease;   Coronary Heart Disease
Interventions:   Drug: Acetylsalicylic Acid (Asprin, BAYE4465);   Drug: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
Sponsor:   Bayer
Recruiting - verified February 2016

NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: NP202;   Other: Placebo
Sponsor:   Armaron Bio Pty Ltd
Recruiting - verified February 2016

Optilene® Suture for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Heart Disease;   Multi Vessel Coronary Artery Disease
Intervention:   Procedure: Coronary Artery Bypass Graft surgery
Sponsors:   Aesculap AG;   B.Braun Surgical SA
Recruiting - verified January 2016

ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts

Conditions:   Coronary Artery Disease;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Aspirin 100 mg;   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients

Condition:   Coronary Arteriosclerosis
Intervention:  
Sponsors:   Acarix;   Steno Diabetes Center;   Rigshospitalet, Denmark
Completed - verified February 2016

Coronary Disease and the Effect of High-intensity Interval Training

Condition:   Coronary Disease
Interventions:   Behavioral: high intensity interval-based aerobic exercise;   Other: Usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Recruiting - verified February 2016

ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE)

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Nurse-led Intensive Secondary Prevention Programme;   Behavioral: Usual Treatment
Sponsor:   Azienda Ospedaliero-Universitaria di Parma
Recruiting - verified February 2016

A Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffold

Condition:   Coronary Artery Disease
Interventions:   Device: Angiography-guided PCI with bioresorbable vascular scaffold;   Device: optical coherence tomography-guided PCI with bioresorbable vascular scaffold
Sponsor:   Yonsei University
Recruiting - verified February 2016

Stress Ulcer Prophylaxis in the Intensive Care Unit

Conditions:   Gastrointestinal Bleeding;   Stress Ulcers
Interventions:   Drug: Pantoprazole;   Other: Saline (0.9%)
Sponsors:   Dr. Morten Hylander Møller;   Rigshospitalet, Denmark;   Copenhagen Trial Unit, Center for Clinical Intervention Research
Recruiting - verified February 2016

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Conditions:   Major Depressive Disorder;   Coronary Artery Disease
Intervention:   Drug: Vortioxetine
Sponsors:   Thomas Jefferson University;   Takeda
Not yet recruiting - verified February 2016

Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease

Condition:   Nonobstructive Coronary Artery Disease
Intervention:   Other: Slow-paced walking
Sponsor:   University of Florida
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

Verapamil vs Heparin in Transradial Procedures

Condition:   Heart Disease, Ischemic
Interventions:   Drug: Heparin;   Drug: Verapamil
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Prospective Registry of Acute Coronary Syndromes in Ferrara

Condition:   Acute Coronary Syndromes
Intervention:   Other: prospective collection of data and follow-up
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

Condition:   Acute Coronary Syndrome (ACS)
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2016

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC);   Drug: Placebo
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified January 2016

An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified January 2016

The RESTORE-SIRIO Randomized Controlled Trial

Conditions:   Percutaneous Coronary Intervention;   No-reflow Phenomen;   Acute ST-segment Elevation Myocardial Infarction
Interventions:   Other: intracoronary epinephrine;   Other: no intracoronary epinephrine
Sponsors:   Heinrich-Heine University, Duesseldorf;   SIRIO MEDICINE
Withdrawn - verified February 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Recruiting - verified February 2016

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Frailty in Elderly Patients Receiving Cardiac Interventional Procedures

Condition:   Frailty
Intervention:   Other: frailty evaluation
Sponsor:   University Hospital of Ferrara
Recruiting - verified September 2015

Prevention of Myocardial Injury in Non-cardiac Surgery

Conditions:   Myocardial Injury;   Myocardial Infarction
Intervention:   Procedure: Remote ischemic preconditioning
Sponsor:   University Hospital Koge
Recruiting - verified February 2016

CSCC_ASC Therapy in Patients With Severe Heart Failure

Condition:   Heart Failure
Intervention:   Biological: Allogeneic adipose derived stem cells (CSCC_ASC)
Sponsor:   JKastrup
Completed - verified February 2016

Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes

Conditions:   Chronic Obstructive Pulmonary Disease;   Acute Coronary Syndromes
Intervention:   Other: screening test
Sponsor:   University Hospital of Ferrara
Active, not recruiting - verified September 2015

Italian Absorb Registry

Condition:   Coronary Artery Disease
Intervention:   Device: PCI with Absorb scaffold
Sponsors:   Ospedale Santa Croce-Carle Cuneo;   Fatebenefratelli and Ophthalmic Hospital;   Bolognini Hospital;   Ospedale Regionale di Aosta;   Ospedali Riuniti di Ancona;   S. Giacomo Hospital;   Azienda U.L.S.S n.9 Ospedale di Treviso Ca Foncello;   Ospedale San Bortolo di Vicenza;   Azienda Ospedaliera Brotzu;   San Giuseppe Moscati Hospital;   Azienda Sanitaria Locale USL 13 Ospedale Mazzoni di Ascoli Piceno;   S. Andrea Hospital;   Ospedale Monaldi di Napoli;   Azienda Ospedaliera di Padova;   Ospedale della Misericordia di Grosseto;   Ospedale Santa Corona di Pietra Ligure;   Istituto di Ricerche Farmacologiche Mario Negri Milano
Active, not recruiting - verified February 2016

Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2016

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

Condition:   ESRD
Interventions:   Drug: anakinra;   Drug: actos;   Other: placebo
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2016

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

Conditions:   Heart Attack;   NSTEMI
Interventions:   Biological: AMI MultiStem cells;   Other: Sham
Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2016

Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Condition:   Hypercholesterolemia
Intervention:   Biological: Evolocumab
Sponsor:   Amgen
Enrolling by invitation - verified February 2016

Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial

Condition:   Kawasaki Disease
Interventions:   Drug: Infliximab;   Drug: IVIG
Sponsors:   Fudan University;   Shanghai Children's Medical Center;   Shanghai 10th People's Hospital;   Shanghai Eighth People's Hospital;   Shanghai Xuhui Distrct Center Hospital
Completed - verified December 2014

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Peripheral Arterial Insufficiency Associated With HIV/AIDS

Conditions:   Arterial Insufficiency;   Acquired Immunodeficiency Syndrome;   HIV
Intervention:   Procedure: Ankle-Brachial index
Sponsor:   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Completed - verified January 2016

Exercise as a Life-long Medicine in Patients With Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Angina (Stable)
Interventions:   Behavioral: high-intensity exercise training;   Behavioral: web-based follow-up program;   Behavioral: usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified February 2016

Off Pump Versus On Pump Coronary Artery Bypass Grafting in Frailty Patients (FRAGILE)

Conditions:   Coronary Artery Disease;   Complications Due to Coronary Artery Bypass Graft;   Fragility
Interventions:   Procedure: OPCAB;   Procedure: CABG
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute;   Cardiac Emergency Hospital of Pernambuco;   Alberto Urquiza Wanderley Hospital of João Pessoa;   Pitangueiras Hospital of Jundiaí;   University of Campinas, Brazil;   Cardiology Institute of the Distrito Federal;   National Cardiology Institute;   Federal University of São Paulo;   Pontifícia Universidade Católica do Paraná;   Clinical Hospital Samuel Libânio of Pouso Alegre;   Beneficência Portuguesa of São Paulo;   Pontifical University Catholic of Campinas;   InCor Heart Institute of Natal
Not yet recruiting - verified January 2016

Multidetector Coronary CT In Vasospastic Angina

Condition:   Vasospastic Angina
Interventions:   Procedure: Positive CAG with EG test;   Procedure: Negative CAG with EG test
Sponsor:   Dong-A University
Recruiting - verified February 2016

Absorb IV Randomized Controlled Trial

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: Absorb BVS;   Device: XIENCE
Sponsor:   Abbott Vascular
Recruiting - verified February 2016

Paraoxonase and HDL Qualities in Glycaemia and Inflammation

Conditions:   Diabetes.;   Bariatric Surgery.
Intervention:  
Sponsors:   Central Manchester University Hospitals NHS Foundation Trust;   British Heart Foundation;   Juvenile Diabetes Research Foundation
Recruiting - verified January 2016

Remote Ischemic Preconditioning With Postconditioning in Heart Transplantation Surgery

Conditions:   Myocardial Ischemic Reperfusion Injury;   End Stage Heart Disease;   Heart Failure;   Cardiomyopathy
Interventions:   Procedure: RIPC+RIPostC;   Procedure: control
Sponsor:   Chinese Academy of Medical Sciences, Fuwai Hospital
Recruiting - verified February 2016

Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients

Condition:   Intra-dialytic Hypotension
Interventions:   Drug: Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate);   Drug: Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
Sponsor:   Brigham and Women's Hospital
Recruiting - verified February 2016

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified January 2016

The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.

Condition:   ST-elevation Myocardial Infarction
Intervention:   Other: Percutaneous coronary intervention
Sponsor:   Chiang Mai University
Completed - verified May 2014

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Percutaneous Coronary Intervention;   Thrombolytic Therapy
Interventions:   Drug: Prourokinase;   Drug: Tirofiban;   Drug: normal saline
Sponsor:   Fudan University
Recruiting - verified February 2016

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Treatment 90 days DAPT;   Drug: Treatment 360 days DAPT
Sponsor:   Diagram B.V.
Recruiting - verified February 2016

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Active, not recruiting - verified February 2016

Early Predictive Factors of Cardiac and Cerebral Involvement in TMA

Conditions:   Thrombotic Microangiopathy,;   Thrombotic Thrombocytopenic Purpura,
Intervention:   Other: Biological and imaging investigations
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified February 2016

Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD

Condition:   Cervical Artery Dissection
Interventions:   Drug: Acetylsalicylic acid;   Drug: vitamin K-antagonist
Sponsors:   University Hospital, Basel, Switzerland;   University Hospital Inselspital, Berne;   University of Lausanne Hospitals
Recruiting - verified February 2016

Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study

Conditions:   Heart Failure;   Myocardial Infarction
Intervention:  
Sponsor:   Mayo Clinic
Recruiting - verified February 2016

Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:   Procedure: Primary Percutaneous Coronary Intervention
Sponsor:   John Pernow
Completed - verified February 2016

Essential Hypotension and Adaptability Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified February 2016

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Condition:   Acute Myocardial Infarction
Interventions:   Drug: liraglutide (Novo Nordisk, Bagsværd, Denmark);   Drug: liraglutide placebo (Novo Nordisk)
Sponsor:   Chen Wei Ren, MD
Recruiting - verified February 2016

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Conditions:   Breast Cancer;   Breast Tumors;   Cancer of Breast
Interventions:   Drug: Metformin;   Drug: Atorvastatin;   Procedure: Breast surgery
Sponsor:   Columbia University
Recruiting - verified February 2016

Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery

Condition:   Patients Undergoing Elective Lumbar Spinal Surgery
Interventions:   Procedure: Remote ischemic preconditioning at left upper arm;   Procedure: Control group
Sponsor:   Yonsei University
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: XIENCE V EECSS;   Device: ABSORB BVS System
Sponsor:   Abbott Vascular
Active, not recruiting - verified January 2016

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Condition:   Coronary Artery Disease
Intervention:   Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor:   Bayer
Active, not recruiting - verified February 2016

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Condition:   Coronary Artery Disease
Intervention:   Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor:   Bayer
Recruiting - verified February 2016

OPtical Frequency Domain Imaging Versus INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging

Condition:   Coronary Artery Disease
Interventions:   Device: OFDI-guided PCI & IVUS;   Device: IVUS-guided PCI & OFDI
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Wakayama Medical University
Active, not recruiting - verified February 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified February 2016

ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.

Conditions:   Chronic Total Occlusion of Coronary Artery;   Coronary Occlusion;   Coronary Artery Disease;   Coronary Artery Restenosis;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Restenosis
Intervention:   Device: Absorb Bioresorbable Vascular Scaffold
Sponsor:   Abbott Vascular
Completed - verified January 2016

GLOBAL Clinical Study

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Global Genomics Group, LLC
Active, not recruiting - verified February 2016

Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting for True Bifurcation Lesions

Condition:   Coronary Heart Disease
Intervention:   Device: Resolute stents
Sponsors:   Fujian Medical University;   Jetmed(Beijing)Co.,Ltd.
Recruiting - verified February 2016

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Patient Reported Outcome Measures for Ablation of Cardiac Arrhythmias

Condition:   Cardiac Arrhythmia
Interventions:   Other: Interview;   Other: Questionnaires
Sponsors:   Cardiff and Vale University Health Board;   National Institute for Health and Clinical Excellence;   University Hospital Birmingham NHS Foundation Trust;   Newcastle-upon-Tyne Hospitals NHS Trust;   University College, London
Active, not recruiting - verified February 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2016

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Condition:   Coronary Heart Disease
Interventions:   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed - verified February 2016

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2016

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Condition:   Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions:   Other: Background care;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

TAKO-TSUBO Cardiomyopathy and Genetic

Conditions:   Tako-TSUBO Cardiomyopathy;   Acute Coronary Syndrome
Intervention:  
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Fédération Française de Cardiologie
Active, not recruiting - verified February 2016

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified January 2016

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions:   Infection;   Hypertension;   Pain;   Reflux;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma;   Withdrawal;   Inflammation;   Bacterial Septicemia;   Cytomegalovirus Retinitis;   Herpes Simplex Virus;   Adenovirus;   Brain Swelling;   Airway Swelling;   Adrenal Insufficiency;   Anxiety;   Nausea;   Vomiting;   Convulsions;   Muscle Spasms;   Seizures;   Epilepsy;   Bartonellosis;   Brucellosis;   Cholera;   Plague;   Psittacosis;   Q Fever;   Relapsing Fever;   Rocky Mountain Spotted Fever;   Trachoma;   Tularemia;   Typhus Fever;   Bronchospasm;   Cardiac Arrest;   Hypersensitivity Reaction;   Cyanide Poisoning;   Acute Bacterial Sinusitis;   Bacterial Meningitis;   Sepsis;   Gastroparesis;   Opioid Addiction;   Migraines;   Headaches
Intervention:   Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation;   OpAns, LLC
Recruiting - verified February 2016

The Role Of Noninvasive 320-Row Multidetector Computer Tomography

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   University Health Network, Toronto;   Mount Sinai Hospital, Canada
Active, not recruiting - verified February 2016

Optimizing Expectations in Cardiac Surgery Patients

Conditions:   Coronary Artery Bypass Graft Surgery (CABG);   Patients' Expectations;   Coronary Heart Disease
Interventions:   Behavioral: Expectation Manipulation Intervention;   Behavioral: Supportive Therapy
Sponsor:   Philipps University Marburg Medical Center
Completed - verified February 2016

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Conditions:   Coronary Artery Disease;   Decreased Left Ventricular Function
Intervention:   Drug: Exenatide
Sponsors:   Charles University, Czech Republic;   Eli Lilly and Company
Completed - verified January 2016

Study of the Natural History of FFR Guided Percutaneous Coronary Intervention

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   St. Jude Medical (Hong Kong) Limited
Recruiting - verified February 2016

Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock

Condition:   Cardiogenic Shock
Intervention:   Drug: epinephrine/norepinephrine
Sponsor:   Central Hospital, Nancy, France
Recruiting - verified February 2016

Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study

Condition:   Erectile Dysfunction Due to Arterial Insufficiency
Intervention:  
Sponsors:   Medtronic Endovascular;   Medtronic
Terminated - verified January 2016

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients

Conditions:   Death;   Stroke;   Low Cardiac Output Syndrome;   Myocardial Infarction;   Renal Failure;   Pulmonary Failure
Interventions:   Other: Remote ischemic preconditioning stimulus;   Other: control
Sponsor:   Queen's University
Completed - verified February 2016

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Procedure: Percutaneous Coronary Intervention (PCI);   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

Condition:   Coronary Heart Disease, Graft Occlusion, Vascular
Interventions:   Drug: Placebo;   Drug: RO4905417
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab

Conditions:   Arthritis, Rheumatoid;   Pain;   Fatigue
Interventions:   Drug: adalimumab;   Drug: Placebo
Sponsors:   Karolinska Institutet;   Abbott;   Swedish Foundation for Strategic Research;   The Swedish Research Council
Recruiting - verified February 2016

Morphine In Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: morphine chlorhydrate;   Drug: saline solution
Sponsors:   French Cardiology Society;   Institut National de la Santé Et de la Recherche Médicale, France
Active, not recruiting - verified February 2016

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Condition:   Cardiovascular Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Terminated - verified February 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease

Conditions:   Myocardial Ischemia;   Coronary Artery Disease;   Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Ventricular Tachycardia (VT) Ablation Versus Enhanced Drug Therapy

Condition:   Recurrent Ventricular Tachycardia
Interventions:   Procedure: Catheter Ablation;   Drug: Aggressive Antiarrhythmic Therapy (Amiodarone)
Sponsors:   John Sapp;   St. Jude Medical;   Biosense Webster, Inc.;   Canadian Institutes of Health Research (CIHR)
Completed - verified January 2016

Safety and Efficacy of SeeMore (TM) in Heart Patients

Condition:   Myocardial Infarction
Intervention:   Drug: SeeMore(TM)
Sponsor:   Eagle Vision Pharmaceutical Corp.
Completed - verified February 2016

Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol

Conditions:   Coronary Artery Disease;   Mitral Valve Regurgitation;   Mitral Valve Incompetence;   Heart Failure
Intervention:   Device: CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
Sponsor:   Edwards Lifesciences
Active, not recruiting - verified February 2016

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition:   Coronary Heart Disease
Interventions:   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Lifetime Risk for Cardiovascular Disease Among Non-White Ethnic Groups

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Failure, Congestive;   Atrial Fibrillation
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 2007

Hostility Reduction Program to Improve Autonomic Regulation of the Heart

Conditions:   Hostility;   Coronary Arteriosclerosis
Intervention:   Behavioral: CBT Hostility Reduction Program
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 2007

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Coronary Heart Disease Incidence: Depression & Inflammation Risk

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Depression;   Inflammation
Intervention:  
Sponsors:   Columbia University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Exercise-training Before Coronary Artery Bypass Graft (CABG)

Conditions:   Angina;   Coronary Artery Disease
Intervention:   Behavioral: Exercise training
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified February 2016

Enhancing Support for Women at Risk for Heart Disease

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Coronary Heart Disease Risk Reduction;   Diabetes Mellitus, Non-insulin Dependent
Interventions:   Behavioral: diet;   Behavioral: physical activity;   Behavioral: stress management;   Behavioral: smoking cessation
Sponsors:   Oregon Research Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Vascular Interaction With Age in Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Drug: L-Arginine
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 2005

Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Coronary Arteriosclerosis;   Coronary Disease;   Cerebrovascular Disorders;   Heart Failure, Congestive;   Myocardial Infarction;   Heart Diseases;   Diabetes Mellitus, Non-insulin Dependent;   Hypertension;   Diabetic Retinopathy;   Macular Degeneration;   Diabetes Mellitus
Intervention:  
Sponsors:   University of Wisconsin, Madison;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA

Conditions:   Cardiovascular Diseases;   Coronary Arteriosclerosis;   Heart Diseases;   Polycystic Ovary Syndrome
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 2005

Retinal Arteriolar Abnormalities and CV Mortality

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Cerebrovascular Disorders;   Coronary Disease
Intervention:  
Sponsors:   University of Wisconsin, Madison;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Minnesota Heart Survey - Mortality and Morbidity

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Death, Sudden, Cardiac
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Anxiety and Vagal Control of the Heart in Coronary Disease

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Depression;   Heart Diseases;   Death, Sudden, Cardiac;   Arrhythmia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2006

Pooling of Cohort Studies on Diet & Coronary Disease

Conditions:   Coronary Arteriosclerosis;   Cardiovascular Diseases;   Heart Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 2004

Coronary Artery Disease Mechanisms in High Risk Families--Racial Difference

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2002

Lupus Cohort--Thrombotic Events and Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Thrombosis;   Heart Diseases;   Lupus Erythematosus, Systemic
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2000

Hyperapo B and Coronary Heart Disease

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Diabetes Mellitus;   Obesity;   Hypercholesterolemia, Familial
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2000

Mediators of Social Support in Coronary Disease

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Depression
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2004

Determinants of Coronary Disease in High Risk Families

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2004

Epidemiology of Coronary Heart Disease in Blacks

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2000

Genetic Epidemiology of Coronary Heart Disease Risk in Women Twins

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2004

Hostility and Pathogenic Mechanisms of Coronary Heart Disease in Women

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2000

Chronic Stress as a Risk Factor in the Etiology of Coronary Heart Disease

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2004

Hostility and Coronary Risk--Role of Weak Vagal Function

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Ischemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2005

Community Site Coronary Risk Control in Black Families

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Coronary Heart Disease Risk Reduction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2005

Population-Based Modeling of Cholesterol Lowering in the United States

Conditions:   Cardiovascular Diseases;   Coronary Heart Disease Risk Reduction;   Heart Diseases;   Coronary Disease;   Hypercholesterolemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified September 2002

Lifestyle Management for Women With CHD and NIDDM

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Diabetes Mellitus, Non-insulin Dependent;   Postmenopause;   Diabetes Mellitus
Intervention:  
Sponsors:   Oregon Research Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Genetic Epidemiology of Hypertriglyceridemia

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Hyperlipidemia, Familial Combined;   Hyperlipoproteinemia Type iv
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2005

Genetics of the Metabolic Syndrome in Japanese Americans

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Insulin Resistance;   Diabetes Mellitus, Non-insulin Dependent;   Diabetes Mellitus;   Metabolic Syndrome X
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2005

Pathobiological Determinants of Atherosclerosis in Youth (PDAY)

Conditions:   Cardiovascular Diseases;   Atherosclerosis;   Heart Diseases;   Coronary Disease;   Coronary Arteriosclerosis
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2008

Race and the Use of Cardiovascular Surgical Procedures

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2002

Minnesota Heart Survey - Risk Factor Survey

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Cerebrovascular Accident;   Coronary Disease;   Hypertension;   Myocardial Infarction
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Visceral Fat, Metabolic Rate, and CHD Risk in Young Adults

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Obesity
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2004

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Cerebrovascular Disorders;   Diabetes Mellitus;   Hypertension;   Cerebrovascular Accident
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2008

Postmenopausal Progestins, MI and Stroke

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Cerebrovascular Accident;   Myocardial Infarction;   Postmenopause
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2000

Homocyst(e)Ine, Vitamin Status, and CVD Risk

Conditions:   Cardiovascular Diseases;   Cerebrovascular Accident;   Coronary Disease;   Myocardial Infarction;   Heart Diseases;   Hyperhomocysteinemia
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2000

Community Structure and Cardiovascular Mortality Trends

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Myocardial Ischemia;   Cerebrovascular Disorders;   Cerebrovascular Accident
Intervention:  
Sponsors:   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

Central Obesity and Disease Risk in Japanese Americans

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Atherosclerosis;   Hypertension;   Obesity;   Diabetes Mellitus, Non-insulin Dependent;   Hyperinsulinism;   Insulin Resistance;   Coronary Arteriosclerosis;   Diabetes Mellitus;   Metabolic Syndrome X
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2004

Novel Hemostatic Cardiac Risk Factors in Framingham

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Death, Sudden, Cardiac;   Myocardial Infarction;   Thrombosis;   Atherosclerosis;   Carotid Artery Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2005

Common Variants in Candidate Genes and Premature MI Risk

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Myocardial Infarction
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2005

Effect of Drug Therapy on Reinfarction Risk in Women

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Heart Diseases
Intervention:  
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2001

HDL-Atherosclerosis Treatment Study (HATS)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Drug: simvastatin;   Drug: niacin;   Drug: antioxidants
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2005

Estrogen and Graft Atherosclerosis Research Trial (EAGER)

Conditions:   Cardiovascular Diseases;   Coronary Arteriosclerosis;   Coronary Disease;   Heart Diseases;   Myocardial Ischemia;   Postmenopause
Interventions:   Drug: hormone replacement therapy;   Drug: estrogens;   Drug: medroxyprogesterone
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2005

Cholesterol Reduction in Seniors Program (CRISP)

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Hypercholesterolemia;   Myocardial Ischemia
Intervention:   Drug: lovastatin
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 1992

Intravenous Streptokinase in Acute Myocardial Infarction

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Myocardial Ischemia
Intervention:   Drug: streptokinase
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified October 1994

Myocardial Infarction Triage and Intervention Project (MITI)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Infarction;   Myocardial Ischemia
Intervention:   Drug: tissue plasminogen activator
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2001

Postmenopausal Hormone Therapy in Unstable Angina

Conditions:   Angina, Unstable;   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Postmenopause
Interventions:   Drug: estrogen replacement therapy;   Drug: estrogens;   Drug: progesterone;   Drug: hormone replacement therapy
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2005